HELX vs OZEM: Holdings Overlap & Returns
Over the year to Nov 13, 2026, HELX returned +22.6% to OZEM's +0.7%; 6% of their weight is in the same names.
- Return gap
- +21.9 pts1 year to Nov 13, 2026: HELX ahead, total return
- Fee gap
- 0.09 ptsA year: HELX 0.50%, OZEM 0.59%, per filings dated Apr 30, 2026 and Jul 27, 2026
- Overlap
- 6%Share of the two books held in common, holdings dated Jun 30, 2026 and Nov 13, 2026
- Net flow
- –Needs daily flows for both funds
Compare two other funds
Growth of 100
Drawn from the numbers on this page. Growth of 100, both funds, distributions reinvested
HELX +22.6%, OZEM +0.7%: HELX +21.9 pts ahead, 1 year, Nov 13, 2025 to Nov 13, 2026.
ShareUse this comparison
Fees over time
Hypothetical. $10,000 in OZEM for 10 years at 0.59% a year costs about $972 in fees and lost growth; HELX at 0.50% would cost $827. Assumes 6% a year before fees, a sample rate, not a forecast.
How each fund moved
15% of HELX's weight is in S&P 500 companies and 85% is outside the index. Holdings as of Jun 30, 2026.
30% of OZEM's weight is in S&P 500 companies and 70% is outside the index. Holdings as of Nov 13, 2026.
Key numbers
HELX costs 0.09 points a year less; their one-year returns differ by 21.9 points; OZEM is 1.7 times larger.
Pair scorecard
Open the table
Points (pts) are percentage points.
| Total return, 1 year | +22.6% | +0.7% |
|---|---|---|
| Below its all-time high | 26.5%, high on Sep 7, 2021 | 15.1%, high on Jan 26, 2026 |
| What it tracks | Healthcare innovation and GLP-1 | Healthcare innovation and GLP-1 |
| Expense ratio | 0.50% | 0.59% |
| Net assets, as of Nov 12, 2026 | $34m | $57m |
| Holdings in common | 6% |
The numbers behind it
Net assets: $34m on Nov 12, 2026 for Franklin Genomic Advancements ETF, and $57m on Nov 13, 2026 for Roundhill GLP-1 & Weight Loss ETF.
Holdings in common uses holdings dated Jun 30, 2026 and Nov 13, 2026.
What they share
By the books each fund has filed, HELX and OZEM hold 6% of their money in the same securities at the same weight. Holdings dated Jun 30, 2026 and Nov 13, 2026.
half
6% in common
Held in common
Show all 2 holdings
| ELI LILLY & COMPANY | 2.95% | 20.30% |
| ASTRAZENECA PLC | 2.70% | 3.22% |
Only in HELX
Show all 8 holdings
| GUARDANT HEALTH INC | 9.09% |
| NATERA INC | 7.46% |
| KRYSTAL BIOTECH INC | 6.33% |
| LIGAND PHARMACEUTICALS INC | 4.62% |
| ADAPTIVE BIOTECHNOLOGIES CORP | 3.99% |
| UNITED THERAPEUTICS CORP | 3.51% |
| BRIDGEBIO PHARMA INC | 3.50% |
| TWIST BIOSCIENCE CORP | 2.85% |
Only in OZEM
Show all 8 holdings
| Novo Nordisk A/S | 10.86% |
| Hanmi Pharm Co Ltd | 6.97% |
| Chugai Pharmaceutical Co Ltd | 6.82% |
| Pfizer Inc | 5.69% |
| Kailera Therapeutics Inc | 4.89% |
| CSPC Pharmaceutical Group Ltd | 4.56% |
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 4.16% |
| Viking Therapeutics Inc | 3.94% |
Side by side
Open the table
| Fund | Franklin Genomic Advancements ETF · Holds 61 stocks in healthcare innovation and GLP-1, 15% of its weight in S&P 500 companies | Roundhill GLP-1 & Weight Loss ETF · Holds 21 stocks in healthcare innovation and GLP-1, 30% of its weight in S&P 500 companies |
| Issuer | Franklin | Roundhill |
| Theme | Healthcare innovation and GLP-1 | Healthcare innovation and GLP-1 |
| In the S&P 500 | 14.9% | 30.4% |
| Active share vs the S&P 500 | 97.2% | 97.8% |
| In the Nasdaq-100 | 7.5% | 4.4% |
| Holdings | 61 | 21 |
| Top ten, share of the fund | 47.1% | 72.0% |
| Expense ratio | 0.50% | 0.59% |
| Fee for the differing part | 0.51% | 0.60% |
| Total return, 1 year | +22.6% | +0.7% |
| vs its benchmark | not measured | not measured |
| Below its high | −26.5% | −15.1% |
| Net assets, HELX as of Nov 12, 2026 and OZEM as of Nov 13, 2026 | $34m | $57m |
As of Nov 13, 2026. Source: ETFIQ.
Window by window
Open the table
| 3 months | +5.0% | −4.9% |
|---|---|---|
| 6 months | +29.7% | +1.8% |
| 1 year | +22.6% | +0.7% |
| 3 years | +57.1% | – |
| Since launch (Not the same days: HELX Feb 2020 · OZEM May 2024) | +78.8% | +25.6% |
– means no data for this window.
About HELX
By weight, 15% of HELX's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 97%. The top ten holdings are 47% of the fund across 61 positions, as filed for Jun 30, 2026.
More
Over the year to Nov 13, 2026 the fund returned +22.6% with distributions reinvested. It sits 26.5% below its all-time high of Sep 7, 2021.
About OZEM
By weight, 30% of OZEM's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 72% of the fund across 21 positions, as published by its issuer for Nov 13, 2026.
More
Over the year to Nov 13, 2026 the fund returned +0.7% with distributions reinvested. It sits 15.1% below its all-time high of Jan 26, 2026.
6% of the two portfolios are the same securities at the same weight.
Questions people ask
Do HELX and OZEM hold the same stocks?
By their latest filings, 6% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.
Other comparisons
Sources
More
Links are sources, not endorsements. A comparison is not a recommendation.
Copy and cite
Cite this pageCitation, APA and Markdown
ETFIQ, HELX against OZEM, data as of Nov 13, 2026. https://etfiq.com/compare/themes/helx-vs-ozem
ETFIQ. (Nov 13, 2026). HELX against OZEM. Retrieved from https://etfiq.com/compare/themes/helx-vs-ozem
[HELX against OZEM (ETFIQ, Nov 13, 2026)](https://etfiq.com/compare/themes/helx-vs-ozem)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.